Table 1 Clinical characteristics of subjects among NGT, IGR, T2DM, non-MetS and MetS groups
From: Peripheral neuropathy is associated with insulin resistance independent of metabolic syndrome
NGT(n = 458) | IGR(n = 1043) | T2DM(n = 534) | no-MetS(n = 1065) | MetS(n = 970) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
non-PN(n = 451) | PN(n = 7) | non-PN(n = 1014) | PN(n = 29) | non-PN(n = 489) | PN(n = 45) | non-PN(n = 1037) | PN(n = 28) | non-PN(n = 917) | PN(n = 53) | |
Male/All | 141/451 | 0/7 | 348/1014 | 9/29 | 217/489 | 13/45* | 391/1037 | 9/28 | 315/917 | 13/53 |
Age(year) | 60.7 ± 11.0 | 76.7 ± 9.7* | 60.7 ± 9.3 | 71.4 ± 9.7* | 63.5 ± 9.7 | 69.6 ± 9.5* | 60.5 ± 10.2 | 76.6 ± 10.6* | 61.7 ± 9.5 | 70.5 ± 9.3* |
Smoking history | 68/451 | 0/7 | 134/1014 | 2/29 | 78/489 | 4/45 | 159/1037 | 1/28 | 121/917 | 5/53 |
Duration of T2DM(years) | — | — | — | — | 4.2 ± 6.3 | 11.2 ± 9.6* | — | — | — | — |
BMI (kg/m2) | 23.5 ± 3.1 | 25.4 ± 4.3 | 24.3 ± 3.4 | 24.3 ± 3.9 | 25.5 ± 3.8 | 25.8 ± 4.3 | 23.1 ± 3.0 | 24.1 ± 4.1 | 25.9 ± 3.4 | 25.8 ± 4.1 |
WC(cm) | 82.4 ± 9.1 | 90.3 ± 11.0 | 85.4 ± 9.6 | 88.0 ± 12.2 | 90.2 ± 10.2 | 92.5 ± 10.5 | 81.6 ± 8.9 | 85.9 ± 12.8 | 90.8 ± 9.0 | 93.2 ± 9.5* |
SBP (mmHg) | 124.1 ± 18.4 | 136.1 ± 19.5 | 126.1 ± 18.6 | 132.4 ± 23.6 | 135.2 ± 20.9 | 139.4 ± 23.0 | 121.5 ± 17.8 | 130.1 ± 21.6* | 135.2 ± 19.1 | 140.0 ± 23.0 |
DBP (mmHg) | 78.7 ± 10.5 | 80.6 ± 10.0 | 79.8 ± 10.2 | 77.4 ± 12.0 | 81.7 ± 10.7 | 79.7 ± 11.0 | 77.1 ± 9.6 | 74.6 ± 10.1 | 83.3 ± 10.4 | 81.3 ± 11.1 |
FBG (mmol/L) | 4.5 ± 0.6 | 4.3 ± 0.3 | 5.4 ± 0.8 | 5.3 ± 0.8 | 7.3 ± 2.7 | 8.1 ± 3.8 | 5.2 ± 1.5 | 5.3 ± 1.4 | 6.2 ± 2.0 | 7.6 ± 3.6* |
HbA1c (%) | 5.4 ± 0.2 | 5.5 ± 0.1 | 5.8 ± 0.3 | 5.7 ± 0.4 | 7.1 ± 1.5 | 7.5 ± 1.6 | 5.8 ± 0.8 | 6.0 ± 0.9 | 6.3 ± 1.2 | 7.0 ± 1.7* |
TG (mmol/L) | 1.5 ± 0.9 | 1.4 ± 0.7 | 1.7 ± 1.0 | 1.4 ± 0.7 | 2.1 ± 1.6 | 1.9 ± 1.6 | 1.3 ± 0.6 | 1.0 ± 0.4* | 2.2 ± 1.4 | 2.0 ± 1.5 |
TC (mmol/L) | 5.2 ± 1.0 | 5.4 ± 0.6 | 5.4 ± 1.0 | 5.1 ± 0.9* | 5.5 ± 1.2 | 5.5 ± 1.3 | 5.3 ± 1.0 | 5.3 ± 1.4 | 5.5 ± 1.1 | 5.3 ± 1.0 |
HDL-C (mmol/L) | 1.4 ± 0.3 | 1.3 ± 0.2 | 1.4 ± 0.3 | 1.3 ± 0.4 | 1.3 ± 0.3 | 1.2 ± 0.3 | 1.5 ± 0.3 | 1.5 ± 0.3 | 1.2 ± 0.3 | 1.2 ± 0.3 |
LDL-C(mmol/L) | 3.1 ± 0.7 | 3.5 ± 0.4 | 3.1 ± 0.7 | 2.9 ± 0.6 | 3.2 ± 0.8 | 3.3 ± 0.9 | 3.1 ± 0.7 | 3.2 ± 1.0 | 3.2 ± 0.8 | 3.2 ± 0.7 |
Treatment of diabetes | — | — | 0.2% | 3.4% | 36.0% | 71.1%* | 4.0% | 17.8%* | 14.9% | 52.8%* |
Treatment of dyslipidemia | 2.9% | 14.3% | 1.1% | 0.0% | 2.2% | 6.7% | 0.9% | 3.6% | 2.8% | 5.7% |
Treatment of hypertension | 22.7% | 28.6% | 22.8% | 44.0%* | 43.6% | 45.5% | 16.0% | 35.3%* | 41.6% | 49.0% |